Skip to search formSkip to main contentSkip to account menu

Guillain-Barré syndrome: clinical profile and management

Seasonal occurrence predominantly in winter is noted and peak flow test may be a predictor of assessing requirement of mechanical ventilation and prognosis, and IVIG treatment is more expensive but is associated with less duration of hospital stay.
View PDF (opens in a new tab)

Biomarkers of Delirium Duration and Delirium Severity in the ICU*

Interleukin-6, -8, and -10, tumor necrosis factor-α, C-reactive protein, and S-100β levels in quartile 4 were negatively associated with delirium-/coma-free days by 1 week and 30 days post enrollment, and in-hospital mortality was not found.
View on Wolters Kluwer (opens in a new tab)

A systems biology approach to the global analysis of transcription factors in colorectal cancer

A comprehensive text mining and computational methodology that focused on discovering new targets of one class of molecular entities, transcription factors (TF), within one particular disease, colorectal cancer (CRC), was developed.
View on Springer (opens in a new tab)

S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit – an exploratory analysis

This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients and may have important implications for refining futureDelirium management strategies in ICU patients.
View PDF (opens in a new tab)

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130

AMR and cyclophosphamide can be safely combined with little activity observed in heavily pretreated SCLC patients, and there was no correlation between topoisomerase IIA amplification or NQO1 polymorphisms and response.
View on Wolters Kluwer (opens in a new tab)

A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

A phase I study of recombinant human IL-18 given with ofatumumab was undertaken in patients with CD20+ lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation, finding no unexpected or dose-limiting toxicities were observed.
View on Wolters Kluwer (opens in a new tab)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)

A 50-year-old woman who was admitted initially with vomiting, hiccups and paraesthesias but was not diagnosed with NMO and presented with a severe progression of the disease was diagnosed to have autoimmune thyroiditis with lymphocytic infiltration of the thyroid which progressed from hyperthyroidism to hypothyroidism.
View PDF (opens in a new tab)

Phase I study of everolimus (E, RAD001) and ganitumab (G, AMG 479) in patients (pts) with advanced solid tumors.

A phase I study to determine the safety, recommended phase II dose, pharmacokinetics, pharmacodynamics, and antitumor efficacy of E with G and found synergism between IGF and mTOR inhibitors has been documented preclinically.
View via Publisher (opens in a new tab)

Abstract P5-18-13: Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+ breast cancer

The combination of trastuzumab + imetelstat is well tolerated and results in decreases in HER2 phosphorylation similar to that seen in preclinical models.
View via Publisher (opens in a new tab)

Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).

The premise of this study is that administration of the IGF-1R inhibitor AMG 479 in conjunction with RAD001 would block this effect of mTOR inhibition, and therefore this drug combination will be clinically synergistic.
View on PubMed (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)